FDA Approves PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia

Sep 4, 2026 - 03:00
 0  0
BURLINGTON, Mass.--(BUSINESS WIRE)--August 31, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) today announced the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0